Enhanced gene therapy for DMD using larger dystrophins and lower vector doses
Ended Project Grant Awarded
- Award ID
- HT94252310976
- Recipient
-
University Of Washington UEI HD1WMN6945W6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,708,955
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Seattle, WA 98195, USA
Award details come from USAspending.gov.
About this award
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University of Washington, a leading research institution, will serve as the prime awardee and will likely leverage its extensive expertise in biomedical research, gene therapy, and clinical translation to drive the project's objectives.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Curi Bio Inc. | $94,332 |
Quick answers
Who received award HT94252310976?
HT94252310976 was awarded to University Of Washington by Defense Health Agency (Department of Defense) on September 15, 2023.
How much is award HT94252310976 worth?
$1,708,955 has been obligated on HT94252310976.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award